Qiagen (QGEN) Tops Q4 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
February 8, 2022 4:05 PM ESTQ4 2021: Net sales grow 2% (+4% constant exchange rates, or CER) to $582 million and adjusted diluted EPS rises 9% to $0.74 ($0.75 CER) - both above outlook Full-year 2021: Net sales grow 20% (+19% CER) to $2.25 billion and adjusted diluted EPS rises 23% to $2.65 ($2.63 CER) - both above outlook 22% CER growth in non-COVID product sales, ahead of target for 20% CER Operating cash flow grows 40% to $639 million, free cash flow rises 38% to $449 million QIAGEN initiates 2022 outlook for at least $2.07 billion net sales CER, including double-digit CER growth in non-COVID products vs.... More
